+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Deep Brain Stimulation Devices Market - Growth, Trends, and Forecast (2019 - 2024)

  • ID: 4774972
  • Report
  • May 2019
  • 112 pages
  • Mordor Intelligence
until Mar 31st 2020
1 of 4


  • Fisher Wallace
  • Medtronic Plc
  • NeuroPace Inc.
  • Renishaw plc
  • MORE
Market Overview

The major factors for the growth of the deep brain stimulation devices market include the rapidly aging population leading to risk and high prevalence of neurological disorders, growing demand for the devices due to the rising popularity of minimally invasive procedures, and availability of technologically advanced deep brain stimulation devices.

Deep Brain Stimulation (DBS) is a widely used treatment for the advanced Parkinson's disease (PD), essential tremor, and dystonia, and its clinical applications. However, in addition to the extension of the clinical applications of DBS over the last three decades, there has been tremendous growth in technology. Therefore, the advent of competition in the DBS industry has led to a surge of innovative technologies. Currently, there are multiple DBS systems that are approved by the European and US regulatory agencies. The US Food and Drug Administration (FDA) has recently approved Boston Scientific Corporation’s Vercise Deep Brain Stimulation (DBS) System. This DBS system is used to treat the symptoms of Parkinson's disease (PD). Therefore, researchers are also improving their existing DBS systems, while developing the next generation of devices. The researchers are targeting DBS to different areas of the brain and studying the treatment in different populations of people living with Parkinson’s. Although, some changes in the new systems have shown improvement in clinical outcomes. Nevertheless, these new developments in DBS technology are encouraging a large patient community and to the health care providers. Hence, all these new advancements in the technologies have to lead to an increase in the deep brain stimulation devices market.

Scope of the Report

As per the scope of this report, deep brain stimulator is a battery-operated medical device called neurostimulator, used in the neurosurgical procedure, which helps to treat a variety of disabling neurological symptoms. The market is segmented by product type, application, end user, and geography.

Key Market Trends

Parkinson’s Disease is the Segment by Application is expected to Dominate the Market

The major factor driving the growth of the segment is the rising prevalence of Parkinson’s diseases across the globe. According to Parkinson’s news in 2018, approximately 1.2 million people in the United States are predicted to have Parkinson’s disease by the year 2030. It is the second-most common neurodegenerative disorder in the United States. Similarly, as per the estimates of the NHS UK, Parkinson's disease is found affecting around 1 in 500 people, which means there are an estimated 127,000 people in the UK with the condition. In addition, there are thousands of patients who go undetected. DBS is the most commonly performed surgical treatment for Parkinson's. It is usually done in people who have had Parkinson's for at least four years and still get a benefit from medication but have motor complications. Furthermore, there is a rising technological advancement is going on in the field of DBS propelling overall growth of the market.

North America is Expected to Dominate the Market

According to the Parkinson’s Foundation Prevalence Project, 930,000 people in the United States will be living with Parkinson disease by the year 2020. The combined direct and indirect costs of Parkinson’s in the United States, including treatment, disability, and similar costs, plus lost income from an inability to work, are estimated at USD 25 billion per year in the United States alone. Hence, a growing burden of Parkinson’s disease on the healthcare system coupled with uncertain economic conditions in the United States has forced the Original Equipment Manufacturers (OEMs) to develop cost-effective devices for the treatment of neurological movement disorders. The US Food and Drug Administration (FDA) has also approved another deep brain stimulation (DBS) device in 2015, for treatment of Parkinson’s disease and essential tremor. The Brio System’s approval has been good news for the Parkinson’s patient community in the market, as it may stimulate more rapid development of DBS technology. Boston Scientific Corporation has received approval from the US Food and Drug Administration (FDA) in Dec 2017, for the Vercise Deep Brain Stimulation (DBS) System. Hence, all these recent product approvals and growing incidences of the Parkinson’s disease have helped in driving the Deep Brain Stimulation Devices Market.

Competitive Landscape

The market studied is a consolidated market owing to the presence of the few major market players. Some of the market players are Abbott Laboratories (St Jude Medical), Beijing PINS Medical Co., Ltd., Boston Scientific Corporation, Fisher Wallace, Functional Neuromodulation, Ltd, Medtronic Plc, NeuroPace Inc., and Renishaw plc
Note: Product cover images may vary from those shown
2 of 4


  • Fisher Wallace
  • Medtronic Plc
  • NeuroPace Inc.
  • Renishaw plc
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rapidly Aging Population Leading to Risk and High Prevalence of Neurological Disorders
4.2.2 Growing Demand for the Devices due to Rising Popularity of Minimally Invasive Procedures
4.2.3 Availability of Technologically Advanced Deep Brain Stimulation Devices
4.3 Market Restraints
4.3.1 Risks Associated with Deep Brain Stimulation Procedures
4.3.2 Implementation of the Government Policies Negatively Affecting the Market
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Product Type
5.1.1 Single Channel Deep Brain Stimulator
5.1.2 Dual Channel Deep Brain Stimulator
5.2 By Application
5.2.1 Parkinson's Disease
5.2.2 Essential Tremor
5.2.3 Obsessive Compulsive Disorder
5.2.4 Epilepsy
5.2.5 Dystonia
5.2.6 Other
5.3 By End User
5.3.1 Hospitals
5.3.2 Ambulatory Surgical centers
5.3.3 Neurological Clinics
5.3.4 Other
5.4 Geography
5.4.1 North America US Canada Mexico
5.4.2 Europe Germany UK France Italy Spain Rest of Europe
5.4.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.4.5 South America Brazil Argentina Argentina

6.1 Company Profiles
6.1.1 Abbott Laboratories (St Jude Medical)
6.1.2 Beijing PINS Medical Co., Ltd.
6.1.3 Boston Scientific Corporation
6.1.4 Fisher Wallace
6.1.5 Functional Neuromodulation, Ltd
6.1.6 Medtronic Plc
6.1.7 NeuroPace Inc.
6.1.8 Renishaw plc

Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Abbott Laboratories (St Jude Medical)
  • Beijing PINS Medical Co., Ltd.
  • Boston Scientific Corporation
  • Fisher Wallace
  • Functional Neuromodulation, Ltd
  • Medtronic Plc
  • NeuroPace Inc.
  • Renishaw plc
Note: Product cover images may vary from those shown